Please provide your email address to receive an email when new articles are posted on . VT-1953, a first-in-class topical immunomodulator, improved malodor associated with malignant fungating wounds ...
CAMBRIDGE, MA, UNITED STATES, January 22, 2025 /EINPresswire.com/ -- • VT-1953 treatment reduces malignant fungating wound-associated malodor over a 14 day period ...
VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound (primary endpoint) (P = 0.002).
VT-1953 treatment significantly reduced malignant fungating wound-associated malodor (primary endpoint) (P<0.001). Patients also reported significant improvements in lesion pain (P<0.001) and Quality ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Holdings, Inc. (HIND), a clinical-stage healthcare holding company, today announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In this consulting ...
Sign up for our newsletter to get the latest on the transformative forces shaping the global economy, delivered every Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results